RO5185426

DRUG6 trials

Sponsors

Hoffmann-La Roche

Conditions

Malignant Melanoma

Phase 1

A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma

CompletedNCT01001299

Hoffmann-La RocheMalignant Melanoma

Start: 2009-11-30End: 2012-02-29Updated: 2017-08-15

A Pharmacokinetic/Pharmacodynamic Study of RO5185426 in Previously Treated Patients With Metastatic Melanoma

CompletedNCT01107418

Hoffmann-La RocheMalignant Melanoma

Start: 2010-05-31End: 2013-02-28Updated: 2015-08-26

A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma

CompletedNCT01164891

Hoffmann-La RocheMalignant Melanoma

Start: 2010-07-31End: 2012-12-31Updated: 2023-04-05

A Study of the Effect of Food on the Pharmacokinetics of Single Dose RO5185426 And the Safety And Efficacy of Continuous Administration in Patients With BRAF V600E Mutation-Positive Metastatic Melanoma

CompletedNCT01264380

Hoffmann-La RocheMalignant Melanoma

Start: 2011-01-31End: 2013-05-31Updated: 2016-11-02

Phase 2

A Study of RO5185426 in Patients With Metastatic Melanoma

CompletedNCT01248936

Hoffmann-La RocheMalignant Melanoma

Start: 2010-12-31End: 2011-10-31Updated: 2016-08-12

A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases

CompletedNCT01253564

Hoffmann-La RocheMalignant Melanoma

Start: 2010-11-22End: 2012-03-14Updated: 2017-07-31

Related Papers

Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics.

2014-07-0139 citations

RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors.

2012-01-01786 citations